TNF and rheumatoid arthritis: Furthermore, the HR of tocilizumab for acute myocardial infarction (AMI) and major adverse cardiovascular events (MACE) was significantly lower than for rituximab in RA patients who failed TNF inhibitors (HR = 0.12, 95% CI 0.02–0.56 for AMI, HR = 0.41, 95% CI 0.23–0.72 for MACE) [85], and the HR was lower for coronary heart disease than abatacept in RA patients aged over 65 years (HR = 0.64, 95% CI 0.41–0.99) [74].